J S Lindholt1, P Norman. 1. Vascular Research Unit, Viborg Hospital, Denmark. jes.s.lindholt@sygehusviborg.dk
Abstract
BACKGROUND: Four randomised controlled trials of screening older men for abdominal aortic aneurysms (AAA) have been completed. A meta-analysis was performed to examine the pooled effects of screening on both mid- and long-term AAA-related and total mortality, and operations for AAA. METHODS: Pooled mid-term (3(1/2)-5 years) and long term (7-15 years) effects were calculated as odds-ratios (ORs) with 95% confidence intervals in fixed effect models. Long-term data from the West Australian trial were limited to all-caurse deaths. Heterogeneity between the studies was assessed by the chi(2)-test. In cases of heterogeneity, random effect models were used. RESULTS: The pooled mid-term analysis showed the offer of screening caused a significant reduction in AAA related mortality (OR=0.56, 95% C.I. 0.44,0.72), and emergency operations (OR=0.55, 95% C.I.: 0.39; 0.76), while the number of elective operations increased significantly (OR=3.27, 95% C.I.: 2.14; 5.00). Overall mortality was reduced, but not significantly (OR=0.94, 95% C.I.: 0.86; 1.02). The long-term results also showed a significant reduction in AAA-related mortality (OR=0.47, 95% C.I.: 0.25; 0.90), overall mortality (OR=0.94, 95% C.I.: 0.92; 0.97) and emergency operations (OR=0.48, 95% C.I.: 0.28; 0.83), while the number of elective operations increased significantly (OR=2.81, 95% C.I.: 2.40; 3.30). CONCLUSION: Population screening for AAA reduces AAA-related and overall mortality, however local differences may exits which could influence cost effectiveness of screening.
BACKGROUND: Four randomised controlled trials of screening older men for abdominal aortic aneurysms (AAA) have been completed. A meta-analysis was performed to examine the pooled effects of screening on both mid- and long-term AAA-related and total mortality, and operations for AAA. METHODS: Pooled mid-term (3(1/2)-5 years) and long term (7-15 years) effects were calculated as odds-ratios (ORs) with 95% confidence intervals in fixed effect models. Long-term data from the West Australian trial were limited to all-caurse deaths. Heterogeneity between the studies was assessed by the chi(2)-test. In cases of heterogeneity, random effect models were used. RESULTS: The pooled mid-term analysis showed the offer of screening caused a significant reduction in AAA related mortality (OR=0.56, 95% C.I. 0.44,0.72), and emergency operations (OR=0.55, 95% C.I.: 0.39; 0.76), while the number of elective operations increased significantly (OR=3.27, 95% C.I.: 2.14; 5.00). Overall mortality was reduced, but not significantly (OR=0.94, 95% C.I.: 0.86; 1.02). The long-term results also showed a significant reduction in AAA-related mortality (OR=0.47, 95% C.I.: 0.25; 0.90), overall mortality (OR=0.94, 95% C.I.: 0.92; 0.97) and emergency operations (OR=0.48, 95% C.I.: 0.28; 0.83), while the number of elective operations increased significantly (OR=2.81, 95% C.I.: 2.40; 3.30). CONCLUSION: Population screening for AAA reduces AAA-related and overall mortality, however local differences may exits which could influence cost effectiveness of screening.
Authors: Ahmed Klink; Fabien Hyafil; James Rudd; Peter Faries; Valentin Fuster; Ziad Mallat; Olivier Meilhac; Willem J M Mulder; Jean-Baptiste Michel; Francesco Ramirez; Gert Storm; Robert Thompson; Irene C Turnbull; Jesus Egido; Jose L Martín-Ventura; Carlos Zaragoza; Didier Letourneur; Zahi A Fayad Journal: Nat Rev Cardiol Date: 2011-02-08 Impact factor: 32.419
Authors: Hans-Henning Eckstein; Dittmar Böckler; Ingo Flessenkämper; Thomas Schmitz-Rixen; Sebastian Debus; Werner Lang Journal: Dtsch Arztebl Int Date: 2009-10-09 Impact factor: 5.594
Authors: Nathan K Itoga; Hataka R Minami; Meenadachi Chelvakumar; Keon Pearson; Matthew M Mell; Eran Bendavid; Douglas K Owens Journal: Vasc Med Date: 2018-01-18 Impact factor: 3.239
Authors: Lucas Mota; Christina L Marcaccio; Kirsten D Dansey; Livia E V M de Guerre; Thomas F X O'Donnell; Peter A Soden; Sara L Zettervall; Marc L Schermerhorn Journal: J Vasc Surg Date: 2021-10-22 Impact factor: 4.268